Table 3.
Genotype frequencies and hepatocellular carcinoma adjusted odd ratios for the TNF-α -1031 T>C, -863 C>A, -857 C>T, -308 G>A, and -238 G>A polymorphisms in hepatocellular carcinoma cases and controls n (%)
| Characteristics | Controls, n = 201 |
HCC cases |
HCC cases with HBV |
||||||
| Cases, n = 157 | AOR (95%CI)1 | P-value | FDR-P-value | Cases, n = 125 | AOR (95%CI)1 | P-value | FDR-P-value | ||
| TNF-α -1031 T>C, rs1799964 | |||||||||
| TT | 121 (60.2) | 99 (63.1) | 1.000 (reference) | 73 (58.4) | 1.000 (reference) | ||||
| TC | 70 (34.8) | 47 (29.9) | 0.796 (0.487-1.301) | 0.362 | 0.586 | 42 (33.6) | 0.922 (0.550-1.544) | 0.756 | 0.960 |
| CC | 10 (5.0) | 11 (7.0) | 1.308 (0.498-3.436) | 0.586 | 0.586 | 10 (8.0) | 1.724 (0.628-4.729) | 0.290 | 0.580 |
| Dominant (TT vs TC + CC) | 0.860 (0.540-1.369) | 0.524 | 0.586 | 1.013 (0.622-1.650) | 0.960 | 0.960 | |||
| Recessive (TT + TC vs CC) | 1.393 (0.540-3.595) | 0.493 | 0.586 | 1.745 (0.649-4.693) | 0.270 | 0.580 | |||
| HWE-P | 0.976 | 0.112 | 0.268 | ||||||
| TNF-α -863 C>A, rs1800630 | |||||||||
| CC | 129 (64.2) | 98 (62.4) | 1.000 (reference) | 74 (59.2) | 1.000 (reference) | ||||
| CA | 62 (30.8) | 53 (33.8) | 1.154 (0.709-1.878) | 0.565 | 0.672 | 46 (36.8) | 1.284 (0.767-2.150) | 0.341 | 0.750 |
| AA | 10 (5.0) | 6 (3.8) | 0.784 (0.255-2.414) | 0.672 | 0.672 | 5 (4.0) | 0.825 (0.253-2.690) | 0.750 | 0.750 |
| Dominant (CC vs CA + AA) | 1.109 (0.695-1.768) | 0.666 | 0.672 | 1.226 (0.749-2.007) | 0.418 | 0.750 | |||
| Recessive (CC + CA vs AA) | 0.734 (0.243-2.222) | 0.584 | 0.672 | 0.760 (0.238-2.428) | 0.643 | 0.750 | |||
| HWE-P | 0.477 | 0.723 | 0.513 | ||||||
| TNF-α -857 C>T, rs1799724 | |||||||||
| CC | 142 (70.6) | 116 (73.9) | 1.000 (reference) | 92 (73.6) | 1.000 (reference) | ||||
| CT | 53 (26.4) | 35 (22.3) | 0.841 (0.493-1.432) | 0.523 | 0.697 | 29 (23.2) | 0.840 (0.477- 1.478) | 0.545 | 0.893 |
| TT | 6 (3.0) | 6 (3.8) | 1.816 (0.428-7.714) | 0.419 | 0.697 | 4 (3.2) | 1.110 (0.226- 5.438) | 0.898 | 0.893 |
| Dominant (CC vs CT + TT) | 0.930 (0.558-1.548) | 0.780 | 0.78 | 0.888 (0.516-1.531) | 0.670 | 0.893 | |||
| Recessive (CC + CT vs TT) | 2.091 (0.494-8.860) | 0.317 | 0.697 | 1.500 (0.312-7.203) | 0.612 | 0.893 | |||
| HWE-P | 0.698 | 0.120 | 0.371 | ||||||
| TNF-α -308 G>A, rs1800629 | |||||||||
| GG | 181 (90.0) | 133 (84.7) | 1.000 (reference) | 108 (86.4) | 1.000 (reference) | ||||
| GA | 18 (9.0) | 23 (14.6) | 1.949 (0.940- 4.040) | 0.073 | 0.178 | 17 (13.6) | 1.779 (0.821-3.853) | 0.144 | 0.430 |
| AA | 2 (1.0) | 1 (0.6) | 0.936 (0.075-11.646) | 0.959 | 0.959 | 0 (0.0) | N/A | 0.995 | 0.995 |
| Dominant (GG vs GA + AA) | 1.841 (0.911-3.720) | 0.089 | 0.178 | 1.610 (0.758-3.419) | 0.215 | 0.430 | |||
| Recessive (GG + GA vs AA) | 0.861 (0.069-10.734) | 0.908 | 0.959 | N/A | 0.995 | 0.995 | |||
| HWE-P | 0.057 | 0.996 | 0.415 | ||||||
| TNF-α -238 G>A, rs 361525 | |||||||||
| GG | 180 (89.6) | 130 (82.8) | 1.000 (reference) | 104 (83.2) | 1.000 (reference) | ||||
| GA | 20 (10.0) | 26 (17.6) | 1.634 (0.821-3.251) | 0.162 | 0.324 | 20 (16.0) | 1.491 (0.713-3.117) | 0.288 | 0.576 |
| AA | 1 (0.5) | 1 (0.6) | N/A | 0.993 | 0.994 | 1 (0.8) | N/A | 0.993 | 0.993 |
| Dominant (GG vs GA + AA) | 1.732 (0.876-3.424) | 0.115 | 0.324 | 1.614 (0.780-3.340) | 0.197 | 0.576 | |||
| Recessive (GG + GA vs AA) | N/A | 0.994 | 0.994 | N/A | 0.993 | 0.993 | |||
| HWE-P | 0.587 | 0.807 | 0.972 | ||||||
1
Adjusted for age, sex, hypertension, diabetes mellitus, drinking status, and smoking status. HCC: Hepatocellular carcinoma; AOR: Adjusted odd ratios; HBV: Hepatitis B virus.